Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (2)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
Thailand (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a d…
The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2…
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and …
Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman
Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven
Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover of…
Changes in the Executive Board of STADA Arzneimittel AG
STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the…
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful
STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5…
STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share
STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid
STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board
STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board
STADA: Significant renewal of Supervisory Board brought forward by two years – Annual General Meeting 2016 postponed to August 26, 2016
STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published
STADA: Legal action against STADA’s Serbian subsidiary has been resolved
STADA: Sales and earnings targets for 2014 at Group level met – crisis in the market region CIS/Eastern Europe requires impairments on goodw…
STADA: Successful financial year 2013 – Adjusted EBITDA reaches new record high – Dividend to increase by 32 percent – 2014 outlook adjusted…
STADA: Preliminary figures show successful financial year 2013 – Dividend to increase by 32 percent – Outlook for 2014 confirmed
STADA: Successfully concluded purchase of the Russian branded product portfolio Aqualor® for the self-medication of sinusitis and sore throa…
STADA: Local insolvency administrator files lawsuit against a subsidiary of STADA Arzneimittel AG
STADA strengthens business activities in Russia with the signing of a contract for the purchase of the branded product portfolio Aqualor® fo…
STADA purchases British OTC manufacturer Thornton & Ross
STADA: Dr. Axel Müller resigns his Executive Board mandate
STADA in exclusive negotiations on the purchase of the British OTC manufacturer Thornton & Ross
STADA: Dr. Matthias Wiedenfels to become Chief Corporate Development and Central Services Officer –
STADA's Executive Board expanded to four …